Back Bay in Nature’s Biopharma Dealmakers on the Radiopharmaceutical Renaissance

“The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.”

Nature’s Biopharma Dealmakers published “The radiopharmaceutical renaissance: radiating hope in cancer therapy” written by Back Bay’s Brianne Sullivan, PhD, Andrew Davis and Back Bay Managing Director Peter Bak, PhD,

This article focuses on the commercial success of second-generation radiopharmaceuticals in oncology and explores how re-ignited interest is resulting in a surge of dealmaking. Given the industry interest, Dr. Sullivan, Mr. Davis and Dr. Bak assess the transactional and investment landscape within the radiopharmaceutical space over the past five years, spanning therapeutics, diagnostics and theranostics.

Read the excerpt article here on Biopharma Dealmakers and download our white paper for the full report.